Market revenue in 2023 | USD 19.0 million |
Market revenue in 2030 | USD 50.7 million |
Growth rate | 15.1% (CAGR from 2023 to 2030) |
Largest segment | Product |
Fastest growing segment | Service |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Product, Service |
Key market players worldwide | AstraZeneca PLC, Caribou Biosciences Inc Ordinary Shares, Cellectis SA, CRISPR Therapeutics AG, Editas Medicine Inc, Roche Holding AG, PerkinElmer, Genscript Biotech Corp Class H, Danaher Corp, Intellia Therapeutics Inc, Lonza Group Ltd, Merck KGaA, Takara Bio Inc, Thermo Fisher Scientific Inc, Cibus Inc Ordinary Shares - Class A, Beam Therapeutics Inc, Vertex Pharmaceuticals Inc, Addgene, EGenesis, Synthego, Mammoth Biosciences, Inscripta, PLANTEDIT, Hera Biotech, Origene Technologies, Recombinetics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to crispr and cas genes market will help companies and investors design strategic landscapes.
Product was the largest segment with a revenue share of 78.42% in 2023. Horizon Databook has segmented the Spain crispr and cas genes market based on product, service covering the revenue growth of each sub-segment from 2018 to 2030.
Numerous conferences and meetings related to CRISPR technology conducted in Spain have helped raise awareness among researchers & biotechnology companies, which is expected to boost market progression in the country.
The conference was attended by researchers, scientists, students, and business delegates, who shared & received knowledge about latest scientific advancements in CRISPR technology. Similarly, a debate titled The role of CRISPR in Personalized Medicine: Legal and Ethical Problems, conducted in December 2017, was attended by almost 400 attendees.
It highlighted the importance of CRISPR-Cas in applied research and discussed legal & ethical issues of genome editing in Spain. Such conferences & meetings can help expand the scope of CRISPR technology and overcome challenges of this technology.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain crispr and cas genes market , including forecasts for subscribers. This country databook contains high-level insights into Spain crispr and cas genes market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account